Frozen Shoulder and Menopause: Why It Clusters and How to Manage It

What Is Frozen Shoulder?

Frozen shoulder, or adhesive capsulitis, is a painful disorder in which the glenohumeral joint capsule becomes inflamed, thickened and progressively contracted. The hallmark is restriction of both active and passive shoulder movement, usually with external rotation affected earliest and most clearly. Patients often report night pain, difficulty dressing, fastening a bra, reaching overhead or placing the hand behind the back. Unlike isolated rotator-cuff pain, the examiner cannot restore near-normal movement simply by moving the relaxed arm for the patient (Kelley et al., 2013; Magee et al., 2021).

The condition affects approximately 2%–5% of the general population and occurs most often between 40 and 60 years—the same age range in which many women enter perimenopause or postmenopause. Its course is commonly described as freezing, frozen and thawing, although real patients do not always follow neat time boundaries. Symptoms can persist for one to three years, and some people retain measurable stiffness after pain has improved (Vita et al., 2024).

Why Does It Cluster Around Menopause?

The overlap is clinically striking, but menopause should be treated as an association rather than a proven single cause. Oestrogen receptors are present in musculoskeletal tissues, and oestrogen influences collagen turnover, inflammatory signalling, pain processing and tissue repair. Fluctuating and then declining oestrogen may therefore create a more inflammation- and fibrosis-prone environment in susceptible shoulder capsules. Sleep disturbance, reduced recovery, loss of muscle mass and changing metabolic health during midlife may further lower tissue capacity (Navarro-Ledesma et al., 2025).

However, age and menopause occur together, making their independent effects difficult to separate. A 2026 pilot study comparing menopausal women who did and did not use hormone therapy found no statistically significant difference in adhesive-capsulitis odds; its purpose was primarily to inform the design of larger studies (Reinke et al., 2026). Thus, current evidence supports biological plausibility and a possible association—not proof that low oestrogen causes frozen shoulder or that menopausal hormone therapy prevents or treats it.

The most established systemic risk factors remain diabetes mellitus and thyroid disease. Other associations include prolonged immobilisation, shoulder trauma or surgery, cardiovascular and neurological disease, and a previous frozen shoulder on the opposite side. In a midlife patient, the best clinical model is therefore multifactorial: hormonal transition may contribute, while metabolic disease, pain sensitivity, sleep and loading history shape individual risk.

Clinical Assessment and Differential Diagnosis

Assessment begins with the pattern of onset, night pain, functional loss, symptom duration, menopause stage and relevant comorbidities. Ask about diabetes, thyroid disease, recent surgery, trauma, prolonged sling use and previous contralateral symptoms. Menopause symptoms may be documented because they influence sleep, recovery and the wider care plan, but they do not establish the shoulder diagnosis.

Examination should compare active and passive range, with particular attention to external rotation, abduction and hand-behind-back reach. A capsular pattern, pain at end range and reduced accessory glenohumeral movement support the diagnosis. Strength may appear reduced because pain and stiffness inhibit effort; a large discrepancy between active and passive movement raises greater suspicion of rotator-cuff or neurological pathology. The Shoulder Pain and Disability Index (SPADI) or another patient-reported measure helps establish baseline disability and monitor change.

Frozen shoulder is primarily a clinical diagnosis. Plain radiographs are useful when fracture, glenohumeral osteoarthritis or calcific tendinopathy must be excluded. Ultrasound or MRI may assist when the presentation is atypical or a rotator-cuff tear is suspected, but imaging should not replace clinical assessment (Lee et al., 2025). Urgent medical review is warranted for fever or a hot swollen joint, unexplained weight loss, a history of cancer, recent major trauma, progressive neurological deficit, or severe unremitting pain unrelated to movement.

Stage-Matched Physiotherapy Management

Management should match tissue irritability rather than force the shoulder through the same protocol at every stage. Education is central: recovery is usually slow, pain does not mean the shoulder is being damaged with every movement, and complete rest can reinforce stiffness. At the same time, repeatedly provoking severe or long-lasting pain can reduce adherence and irritate an already sensitive shoulder.

Medical and Multidisciplinary Options

Analgesics or non-steroidal anti-inflammatory drugs may help short-term pain when medically appropriate, but prescribing belongs to the treating clinician. Intra-articular corticosteroid injection can provide short-term pain and functional benefit, particularly during the painful early phase, and combining injection with an appropriately dosed rehabilitation programme is often more useful than relying on either intervention alone. Hydrodilatation may be considered when restriction remains substantial; evidence supports possible short- to medium-term gains, although techniques and comparative results vary (Lee et al., 2025; Vita et al., 2024).

Manipulation under anaesthesia or arthroscopic capsular release is reserved for persistent, severe restriction after an adequate trial of conservative care. These procedures still require postoperative rehabilitation to preserve movement. Menopausal hormone therapy should not be initiated solely for frozen shoulder on present evidence. If a patient has bothersome vasomotor, sleep, genitourinary or other menopause symptoms, referral to a menopause-informed medical clinician allows an individual assessment of benefits, risks and contraindications; the shoulder problem can then be managed in parallel (Reinke et al., 2026).

Prognosis, Prevention and Patient Advice

Most patients improve, but the phrase “self-limiting” can be misleading because pain, sleep disruption and disability may last many months. Progress is rarely linear. Monitor night pain, function, active and passive range, and the response later that day and the following morning. A temporary mild stretch response is acceptable; a marked flare that persists into the next day suggests that intensity or volume should be reduced.

Frozen shoulder cannot always be prevented. Practical risk reduction includes maintaining comfortable shoulder movement after injury or surgery, avoiding unnecessary prolonged immobilisation, and managing diabetes and thyroid disease. Midlife women should seek assessment when progressive stiffness accompanies shoulder pain rather than assuming it is an unavoidable part of menopause. Early recognition supports appropriate pain control, realistic education and timely rehabilitation.

Viva-Ready Summary

• Frozen shoulder causes progressive pain and restriction of both active and passive glenohumeral movement, especially external rotation.
• Its peak age overlaps with perimenopause and menopause; oestrogen-related inflammatory and connective-tissue mechanisms are plausible, but causation is not established.
• Screen particularly for diabetes, thyroid disease, trauma, surgery, immobilisation and the opposite shoulder.
• Diagnosis is clinical; imaging mainly excludes competing pathology or clarifies atypical presentations.
• Physiotherapy should be stage- and irritability-matched: protect an irritable shoulder, then progressively restore mobility, strength and function.
• Injection or hydrodilatation may support rehabilitation in selected patients; surgery is usually reserved for refractory cases.
• Hormone therapy is not currently an evidence-based treatment for frozen shoulder and requires a separate, individualised menopause consultation.

One-line recall: Frozen shoulder near menopause is a stage-sensitive capsular disorder with a plausible hormonal association—not proof of hormonal causation.

References

Kelley, M. J., Shaffer, M. A., Kuhn, J. E., Michener, L. A., Seitz, A. L., Uhl, T. L., Godges, J. J., & McClure, P. W. (2013). Shoulder pain and mobility deficits: Adhesive capsulitis. Journal of Orthopaedic & Sports Physical Therapy, 43(5), A1–A31. https://doi.org/10.2519/jospt.2013.0302

Lee, B. C., et al. (2025). Clinical practice guidelines for diagnosis and non-surgical treatment of primary frozen shoulder. Annals of Rehabilitation Medicine, 49(3), 123–142. https://doi.org/10.5535/arm.250057

Magee, D. J., Zachazewski, J. E., Quillen, W. S., & Manske, R. C. (2021). Pathology and intervention in musculoskeletal rehabilitation (3rd ed.). Elsevier.

Navarro-Ledesma, S., et al. (2025). Frozen shoulder as a systemic immunometabolic disorder: A narrative review. Journal of Clinical Medicine, 14, 7510. https://doi.org/10.3390/jcm14217510

Reinke, E. K., Ford, A. C., Wahl, E., et al. (2026). A preliminary pilot study to address design issues related to research on the potential association of hormone therapy and adhesive capsulitis. Climacteric, 29(3), 1–6. https://doi.org/10.1080/13697137.2026.2615391

Vita, F., Pederiva, D., Tedeschi, R., et al. (2024). Adhesive capsulitis: The importance of early diagnosis and treatment. Journal of Ultrasound, 27, 579–587. https://doi.org/10.1007/s40477-024-00891-y